Clinical study on the combination therapy of pramipexole and madopar for advanced Parkinson's disease in the elderly

Objective To evaluate the efficacy and safety of the combination therapy of pramipexole and madopar for advanced Parkinson's disease in the elderly.Methods Eighty-six patients were randomly divided into piribedil group receiving piribedil and madopar treatment,and pramipexole group receiving pramipexole and madopar treatment,with 43 cases in each group.The course of treatment was 12 weeks.UPDRS Ⅱ,Ⅲ,Ⅳ scores were recorded 4,8,12 weeks after the treatment.The efficacy and adverse reactions were recorded 12 weeks after treatment.Results Compared with the baseline level,UPDRS Ⅱ,Ⅲ,Ⅳ scores 4,8,12 weeks after treatment were significantly decreased in pramipexole group(P0.05).There were no significant differences in the changes of UPDRS Ⅱ,Ⅲ,Ⅳ scores between pramipexole group and piribedil group(P0.05).There were significant differences in the total efficient rate of the switching phenomenon,dyskinesia(P0.05),and no significant difference(P0.05)in the adverse reaction between the two groups.Conclusions Pramipexole is effective and safe in treatment for advanced Parkinson's disease in elderly patients.